Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 19:13:865265.
doi: 10.3389/fneur.2022.865265. eCollection 2022.

Association of MicroRNAs With Risk of Stroke: A Meta-Analysis

Yidong Deng  1 , Peijian Huang  1 , Fan Zhang  1 , Tao Chen  1
Affiliations

Association of MicroRNAs With Risk of Stroke: A Meta-Analysis

Yidong Deng et al. Front Neurol. .

Abstract

Objectives: Altered expression of microRNAs (miRNAs) may contribute to disease vulnerability. Studies have reported the involvement of miRNA in the pathophysiology of ischemic stroke.

Methods: We performed a meta-analysis of data from 6 studies that used a panel of miRNAs with altered expressions to diagnose ischemic stroke with the Bayesian framework. The I 2 test and Cochran's Q-statistic were used to assess heterogeneity. Funnel plots were generated and publication bias was assessed using Begg and Egger tests.

Results: On summary receiver operating characteristics (SROC) curve analysis, the pooled sensitivity and specificity of altered miRNA expressions for diagnosis of ischemic stroke was 0.92 (95% confidence interval [CI] 0.80-0.97) and 0.83 (95% CI 0.71-0.90), respectively; the diagnostic odds ratio was 54.35 (95% CI 20.39-144.92), and the area under the SROC curve was 0.93 (95% CI 0.90-0.95).

Conclusions: Our results showed a link between dysregulation of miRNAs and the occurrence of ischemic stroke. Abnormal miRNA expression may be a potential biomarker for ischemic stroke.

Keywords: diagnostic odds ratio; ischemic stroke; meta-analysis; microRNA; sensitivity.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Schematic illustration of the study selection process.
Figure 2
Figure 2
Forrest plot of estimates of sensitivity and specificity.
Figure 3
Figure 3
Forrest plot of diagnostic odds ratio (DOR).
Figure 4
Figure 4
Summary receiver operating characteristic (SROC) curve.
Figure 5
Figure 5
Fagan's Nomogram for assessment of post-test probabilities.
Figure 6
Figure 6
Forrest plot of risk ratio of miRNAs in different stages of stroke.
Figure 7
Figure 7
Summary receiver operating characteristic curve.
See this image and copyright information in PMC

References

    1. Rink C, Khanna S. MicroRNA in ischemic stroke etiology and pathology. Physiol Genomics. (2011) 43:521–8. 10.1152/physiolgenomics.00158.2010 - DOI - PMC - PubMed
    1. Vasudeva K, Balyan R, Munshi A. ACE-triggered hypertension incites stroke: genetic, molecular, and therapeutic aspects. Neuromolecular Med. (2020) 22:194–209. 10.1007/s12017-019-08583-1 - DOI - PubMed
    1. Koutsis G, Siasos G, Spengos K. The emerging role of microRNA in stroke. Curr Top Med Chem. (2013) 13:1573–88. 10.2174/15680266113139990106 - DOI - PubMed
    1. Qian Y, Chopp M, Chen J. Emerging role of microRNAs in ischemic stroke with comorbidities. Exp Neurol. (2020) 331:113382. 10.1016/j.expneurol.2020.113382 - DOI - PubMed
    1. Chavda V, Madhwani K. Coding and non-coding nucleotides': the future of stroke gene therapeutics. Genomics. (2021) 113:1291–307. 10.1016/j.ygeno.2021.03.003 - DOI - PubMed

Publication types

LinkOut - more resources